Rocket Pharmaceuticals, Inc. (RCKT) financial statements (2022 and earlier)

Company profile

Business Address 350 FIFTH AVENUE
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:388,700482,700304,100213,132100,014126,473111,280
Cash and cash equivalents232,694297,098185,383111,35578,72029,79880,042
Short-term investments156,046185,621118,73294,37521,29496,67531,238
Other undisclosed cash, cash equivalents, and short-term investments(40)(19)(15)7,402   
Deferred costs      1,620
Other undisclosed current assets3,3594,6453,654(4,044)1,0331,876(534)
Total current assets:392,059487,345307,754209,088101,047128,349112,366
Noncurrent Assets
Finance lease, right-of-use asset48,48050,521 
Operating lease, right-of-use asset1,5699142,051
Property, plant and equipment22,29919,20629,2952,0275631,130812
Long-term investments and receivables   7,402   
Long-term investments   7,402   
Intangible assets, net (including goodwill)30,81530,81530,81530,815   
Goodwill30,81530,81530,81530,815   
Deposits noncurrent assets455455455545   
Restricted cash and investments1,3431,5681,5251,436   
Other noncurrent assets    168168143
Other undisclosed noncurrent assets  226    
Total noncurrent assets:104,961103,47964,36742,2257311,298955
TOTAL ASSETS:497,020590,824372,121251,313101,778129,647113,321
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:19,61525,47217,35215,3724,0707,2124,141
Accounts payable7251,4564,424 4511,5921,633
Accrued liabilities1,6782,1678931,2792,3734,4162,508
Employee-related liabilities4,5334,8752,5881,904   
Interest and dividends payable 1,1221,2411,2411,2461,204 
Other undisclosed accounts payable and accrued liabilities12,67915,8528,20610,948   
Debt1,6896,519957    
Other undisclosed current liabilities863626     
Total current liabilities:22,16732,61718,30915,3724,0707,2124,141
Noncurrent Liabilities
Long-term debt and lease obligation20,04954,55246,49241,447   
Long-term debt, excluding current maturities 35,06645,04941,447   
Finance lease, liability19,14418,988 
Operating lease, liability9054981,443
Liabilities, other than long-term debt8013623457403307367
Deferred rent credit   457
Other liabilities8013623 403307367
Other undisclosed noncurrent liabilities    49,54148,960 
Total noncurrent liabilities:20,12954,68846,51541,90449,94449,267367
Total liabilities:42,29687,30564,82457,27654,01456,4794,508
Stockholders' equity
Stockholders' equity attributable to parent454,724503,519307,297194,03747,76473,168108,813
Common stock64561054845268270264
Treasury stock, value  (53)(668)   
Additional paid in capital946,152825,794489,925300,253316,086311,829304,583
Accumulated other comprehensive income (loss)(161)(42)20(127)(16)(54)(11)
Accumulated deficit(491,912)(322,843)(183,143)(105,873)(268,374)(238,877)(196,023)
Total stockholders' equity:454,724503,519307,297194,03747,76473,168108,813
TOTAL LIABILITIES AND EQUITY:497,020590,824372,121251,313101,778129,647113,321

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:(1,200)      
Operating expenses(167,248)(134,303)(76,151)(71,156)(26,737)(41,879)(20,396)
Other undisclosed operating income1,200      
Operating loss:(167,248)(134,303)(76,151)(71,156)(26,737)(41,879)(20,396)
Nonoperating income
(Investment Income, Nonoperating)
    81944389
Interest and debt expense(2,977)(6,967)(5,958)(6,039)(3,579)(1,418)(1,230)
Net loss:(170,225)(141,270)(82,109)(77,195)(29,497)(42,854)(21,537)
Other undisclosed net income (loss) attributable to parent1,1561,5704,8392,677  (46,445)
Net loss attributable to parent:(169,069)(139,700)(77,270)(74,518)(29,497)(42,854)(67,982)
Preferred stock dividends and other adjustments      (131)
Net loss available to common stockholders, diluted:(169,069)(139,700)(77,270)(74,518)(29,497)(42,854)(68,113)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(170,225)(141,270)(82,109)(77,195)(29,497)(42,854)(21,537)
Other undisclosed comprehensive income (loss)    38(43)(46,456)
Comprehensive loss:(170,225)(141,270)(82,109)(77,195)(29,459)(42,897)(67,993)
Other undisclosed comprehensive income, net of tax, attributable to parent1,0371,5084,9862,550   
Comprehensive loss, net of tax, attributable to parent:(169,188)(139,762)(77,123)(74,645)(29,459)(42,897)(67,993)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: